... in the Central Tables 1 and 2 . LMWH, low-molecular-weight heparin; OAC, oral anticoagulation; UFH, unfractionated heparin. Obesity Obesity classes Underweight BMI Antithrombotic drugs Antiplatelet drugs Cardiovascular diseases Cardiovascular diseases Drug variability Artificial...

... of patients with very recent acute coronary syndrome, i.e. <3 months, in whom low-dose ASA may be considered, as shown in Tables 3 and 4 . Antiplatelet drugs Anticoagulant drugs Sepsis Infections Sepsis-induced coagulopathy The scope of this clinical consensus statement...

... in a multicenter-international prospective registry (HOPE-COVID19). Clinical data and in-hospital complications were recorded. AP regimen, including aspirin and other antiplatelet drugs, was obtained for each patient. Results During hospitalization 730 (9.3%) patients received AP drugs with single (93%, n=680...

...P Jariwala; K Jadhav; K Jadhav 3000 Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Antiplatelet Drugs Impact of DAPT duration on clinical outcome after stent implantation for coronary bifurcation lesions: multicentre experience P. Jariwala, K. Jadhav, K. Jadhav Yashoda Hospital...

... encourage the use of DAT rather than TAT in patients with ACS and/or patients requiring PCI with AF who require combined antiplatelet and anticoagulant therapy. Funding Acknowledgement Type of funding sources: None. Major bleeding risk Antiplatelet Drugs 2994 Pharmacology and Pharmacotherapy...

... Acknowledgement Type of funding sources: None. Antiplatelet Drugs 2998 Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Antiplatelet Drugs Ef cacy and safety of early aspirin withdrawal and continuation of ticagrelor monotherapy post PCI for STEMI. A post hoc analysis of the randomized global...

.... Funding Acknowledgement Type of funding sources: None. Table, panel A Table, panel B Antiplatelet Drugs 2996 Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Antiplatelet Drugs Dual antiplatelet therapy with 3rd generation P2Y12 inhibitors in STEMI patients: impact of Body Mass...

... Drugs Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Antiplatelet Drugs 3001 Differences of gastrointestinal bleeding after percutaneous coronary intervention with stent implantation among the different dual anti platelet therapies U. Idiazabal1, A. Ruiz Rodriguez1, I. Pereiro Lili1...

... Drugs Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Antiplatelet Drugs 2993 Ef cacy and safety of dual pathway inhibition in patients with cardiovascular disease M. Galli1, D. Capodanno2, D. D Amario1, F. Andreotti1, F. Crea1, D.J. Angiolillo3 1Catholic University of the Sacred...

...(s): TBA Figure 1. Ticagrelor and AM pharmacokinetics Figure 2. Ticagrelor pharmacodynamics Antiplatelet Drugs Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Antiplatelet Drugs 2991 Lignocaine versus opioids in coronary intervention: assessing antiplatelet activity...

... to subgroups. Funding Acknowledgement Type of funding sources: None. Antiplatelet Drugs 2992 Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Antiplatelet Drugs Frequency of antiplatelet therapy in coronary artery disease. Data from the disease management programme CAD B. Hagen1, R...

... mortality among patients with T2DM. MiR-223, miR-126 and Let-7e present significant interactions with antiplatelet treatment and clinical outcomes. Funding Acknowledgement Type of funding sources: None. Figure 1 Table 1 Antiplatelet Drugs Pharmacology and Pharmacotherapy Cardiovascular...

...H Fukaya; J Ako; S Yasuda; K Kaikita; M Akao; T Matoba; M Nakamura; K Miyauchi; N Hagiwara; K Kimura; A Hirayama; K Matsui; H Ogawa; the AFIRE Investigators Antiplatelet Drugs Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Antiplatelet Drugs 2997 Aspirin vs. P2Y12 inhibitors...

..., further research is needed to confirm/refute our findings. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Bayer AG Antiplatelet Drugs Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Antiplatelet Drugs 2995 Renal decline in patients...

...-6 (pg/mL) 130.4 0–6.99 (pg/mL) a Evening sample few hours after bleeding. b Post blood transfusion. SRH is a rare and catastrophic complication of anticoagulant and antiplatelet drugs of unclear aetiology. The risk of SRH increases in patients of old age, anaemia, sepsis...

..., in-stent restenosis. Acute coronary syndromes Chronic coronary syndromes Myocardial infarction Coronavirus disease 19 Clinical practice guidelines Drug-eluting stents Drug-coated balloons Antiplatelet drugs Coronary revascularization Stent thrombosis Left main coronary artery In-stent restenosis...

..., glycaemic control, and lifestyle characteristics may also reduce stroke risk. Overall, a multifaceted approach is essential to best prevent stroke in patients with CCS/PAD. Stroke Myocardial infarction Coronary artery disease Peripheral arterial disease Antiplatelet drugs Anticoagulant drugs Aspirin...

... clinicians identifying the antithrombotic regimen intensity with the best benefit–risk ratio in an individual patient. Anticoagulation Antiplatelet drugs Dabigatran PCI Coronary heart disease Atrial fibrillation Boehringer Ingelheim 10.13039/100008349 Coronary stenting in patients with the need...

... of clinically relevant bleeding in patients who were at high-risk for ischemic or bleeding events. Funding Acknowledgement Type of funding source: Foundation. Main funding source(s): Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) Antiplatelet Drugs Cardiovascular...

...) Group; F.G Lima; ANtiplatelet Therapy Study (ANTS) Group; A Franci; ANtiplatelet Therapy Study (ANTS) Group; R.H.M Furtado; ANtiplatelet Therapy Study (ANTS) Group; J.C Nicolau; ANtiplatelet Therapy Study (ANTS) Group Antiplatelet Drugs Published on behalf of the European Society of Cardiology. All...